Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis

Javier A. Menendez, Ruth Lupu

Research output: Contribution to journalArticle

1447 Scopus citations

Abstract

There is a renewed interest in the ultimate role of fatty acid synthase (FASN) - a key lipogenic enzyme catalysing the terminal steps in the de novo biogenesis of fatty acids - in cancer pathogenesis. Tumour-associated FASN, by conferring growth and survival advantages rather than functioning as an anabolic energy-storage pathway, appears to necessarily accompany the natural history of most human cancers. A recent identification of cross-talk between FASN and well-established cancer-controlling networks begins to delineate the oncogenic nature of FASN-driven lipogenesis. FASN, a nearly-universal druggable target in many human carcinomas and their precursor lesions, offers new therapeutic opportunities for metabolically treating and preventing cancer.

Original languageEnglish (US)
Pages (from-to)763-777
Number of pages15
JournalNature Reviews Cancer
Volume7
Issue number10
DOIs
StatePublished - Oct 2007
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research

Cite this